ImprimisRx offers a look at three new products in the pipeline

ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.

Making the grade: FDA approves first biosimilar product for retinal diseases

The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).

Advancement in TED treatment is a bright spot

FDA approval of teprotumumab as therapeutic offers hope for patients.

(AAO) Genentech provides update on presentations, product portfolio

November 13, 2020

Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of the company’s podium presentations from the PDS with ranibizumab to faricimab.